Bank of New York Mellon’s Immunic IMUX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,836
| Closed | -$31.5K | – | 4366 |
|
|
2026
Q1 | $31.5K | Sell |
2,836
-210
| -7% | -$1.88K | ﹤0.01% | 4160 |
|
|
2025
Q4 | $16.3K | Hold |
3,046
| – | – | ﹤0.01% | 4170 |
|
|
2025
Q3 | $26.9K | Hold |
3,046
| – | – | ﹤0.01% | 4155 |
|
|
2025
Q2 | $21.2K | Sell |
3,046
-132
| -4% | -$1.21K | ﹤0.01% | 4112 |
|
|
2025
Q1 | $34.6K | Hold |
3,178
| – | – | ﹤0.01% | 4069 |
|
|
2024
Q4 | $31.8K | Hold |
3,178
| – | – | ﹤0.01% | 4094 |
|
|
2024
Q3 | $52.4K | Hold |
3,178
| – | – | ﹤0.01% | 4045 |
|
|
2024
Q2 | $35.3K | Hold |
3,178
| – | – | ﹤0.01% | 4069 |
|
|
2024
Q1 | $41.9K | Buy |
3,178
+474
| +18% | +$6.16K | ﹤0.01% | 4098 |
|
|
2023
Q4 | $40.6K | Hold |
2,704
| – | – | ﹤0.01% | 4175 |
|
|
2023
Q3 | $39.7K | Hold |
2,704
| – | – | ﹤0.01% | 4183 |
|
|
2023
Q2 | $67.9K | Hold |
2,704
| – | – | ﹤0.01% | 4130 |
|
|
2023
Q1 | $40.3K | Hold |
2,704
| – | – | ﹤0.01% | 4227 |
|
|
2022
Q4 | $37.9K | Hold |
2,704
| – | – | ﹤0.01% | 4277 |
|
|
2022
Q3 | $85K | Sell |
2,704
-1
| -0% | -$42 | ﹤0.01% | 4229 |
|
|
2022
Q2 | $94K | Sell |
2,705
-5,164
| -66% | -$331K | ﹤0.01% | 4235 |
|
|
2022
Q1 | $889K | Sell |
7,869
-284
| -3% | -$32.9K | ﹤0.01% | 3383 |
|
|
2021
Q4 | $779K | Buy |
8,153
+1,131
| +16% | +$102K | ﹤0.01% | 3529 |
|
|
2021
Q3 | $621K | Buy |
7,022
+739
| +12% | +$72.7K | ﹤0.01% | 3675 |
|
|
2021
Q2 | $771K | Buy |
6,283
+2,200
| +54% | +$304K | ﹤0.01% | 3567 |
|
|
2021
Q1 | $651K | Buy |
4,083
+37
| +0.9% | +$6.28K | ﹤0.01% | 3548 |
|
|
2020
Q4 | $619K | Buy |
4,046
+515
| +15% | +$92.5K | ﹤0.01% | 3505 |
|
|
2020
Q3 | $656K | Buy |
+3,531
| New | +$578K | ﹤0.01% | 3353 |
|
|
2019
Q2 | – | Sell |
-230
| Closed | -$18K | – | 4245 |
|
|
2019
Q1 | $18K | Sell |
230
-2
| -0.9% | -$176 | ﹤0.01% | 4171 |
|
|
2018
Q4 | $18K | Sell |
232
-13
| -5% | -$1.52K | ﹤0.01% | 4166 |
|
|
2018
Q3 | $27K | Buy |
245
+25
| +11% | +$65.3K | ﹤0.01% | 4190 |
|
|
2018
Q2 | $602K | Buy |
220
+137
| +165% | +$317K | ﹤0.01% | 3539 |
|
|
2018
Q1 | $227K | Buy |
83
+16
| +24% | +$36.7K | ﹤0.01% | 3893 |
|
|
2017
Q4 | $159K | Buy |
67
+4
| +6% | +$8.84K | ﹤0.01% | 3997 |
|
|
2017
Q3 | $127K | Sell |
63
-1
| -2% | -$1.3K | ﹤0.01% | 3968 |
|
|
2017
Q2 | $75K | Sell |
64
-156
| -71% | -$208K | ﹤0.01% | 4077 |
|
|
2017
Q1 | $352K | Buy |
220
+23
| +12% | +$42.1K | ﹤0.01% | 3698 |
|
|
2016
Q4 | $344K | Buy |
197
+2
| +1% | +$4.38K | ﹤0.01% | 3738 |
|
|
2016
Q3 | $478K | Sell |
195
-9
| -4% | -$22.2K | ﹤0.01% | 3564 |
|
|
2016
Q2 | $505K | Buy |
204
+5
| +3% | +$16.4K | ﹤0.01% | 3531 |
|
|
2016
Q1 | $722K | Buy |
199
+3
| +2% | +$10.4K | ﹤0.01% | 3250 |
|
|
2015
Q4 | $903K | Buy |
196
+41
| +26% | +$134K | ﹤0.01% | 3235 |
|
|
2015
Q3 | $250K | Sell |
155
-43
| -22% | -$215K | ﹤0.01% | 3830 |
|
|
2015
Q2 | $1.67M | Buy |
198
+90
| +83% | +$859K | ﹤0.01% | 3040 |
|
|
2015
Q1 | $1.08M | Buy |
108
+16
| +17% | +$147K | ﹤0.01% | 3265 |
|
|
2014
Q4 | $920K | Buy |
92
+42
| +84% | +$323K | ﹤0.01% | 3354 |
|
|
2014
Q3 | $408K | Buy |
50
+3
| +6% | +$28.3K | ﹤0.01% | 3697 |
|
|
2014
Q2 | $517K | Buy |
+47
| New | +$330K | ﹤0.01% | 3597 |
|
Other funds holding IMUX
QC
SAM
AA
CUAMC
SS
Bank of New York Mellon's IMUX Position: Q2 2026 in Review
Bank of New York Mellon sold out of Immunic (IMUX) in Q2 2026, closing a stake of 2,836 shares — an estimated $31.5K sold.
Bank of New York Mellon first reported a position in IMUX in Q2 2014 and held it in 43 quarters. The position peaked at $1.67M in Q2 2015. 12 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.
- Bank of New York Mellon reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 2,836 Immunic shares in Q2 2026, an estimated $31.5K.
- Bank of New York Mellon first reported a position in Immunic in Q2 2014 and held it in 43 quarters.
- Bank of New York Mellon's Immunic position peaked at $1.67M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Immunic as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.